Stay updated on GEMINI 1 Tolebrutinib Clinical Trial
Sign up to get notified when there's something new on the GEMINI 1 Tolebrutinib Clinical Trial page.

Latest updates to the GEMINI 1 Tolebrutinib Clinical Trial page
- Check6 days agoChange DetectedThe page displays the completed GEMINI 1 Phase 3 study record for tolebrutinib in relapsing multiple sclerosis, including study results, eligibility criteria, locations, and links to supporting documents.SummaryDifference100%

- Check13 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the footer revision number changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe ClinicalTrials.gov footer revision advanced from v3.7.0 to v3.7.1 while the page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error with a minimal header and a Home button, replacing the expected study record details. This indicates restricted access to the content rather than an update to the study data.SummaryDifference17%

- Check62 days agoChange DetectedThe page revision tag was updated to v3.7.0, indicating a newer iteration of the site template or rendering. The change does not modify the study details or user-facing content.SummaryDifference0.0%

Stay in the know with updates to GEMINI 1 Tolebrutinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GEMINI 1 Tolebrutinib Clinical Trial page.